PDCD1 and cancer: Tertiary lymphoid structures are not a novelty in the autoimmune and tumor-inflammatory fields, but interest in them has greatly increased with the application of anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapies in malignant tumors.